These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 31981071)

  • 1. A multi-center phase II trial evaluating the efficacy of palbociclib in combination with carboplatin for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma.
    Swiecicki PL; Durm G; Bellile E; Bhangale A; Brenner JC; Worden FP
    Invest New Drugs; 2020 Oct; 38(5):1550-1558. PubMed ID: 31981071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.
    Adkins D; Ley J; Neupane P; Worden F; Sacco AG; Palka K; Grilley-Olson JE; Maggiore R; Salama NN; Trinkaus K; Van Tine BA; Steuer CE; Saba NF; Oppelt P
    Lancet Oncol; 2019 Sep; 20(9):1295-1305. PubMed ID: 31351869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of axitinib in metastatic head and neck cancer with novel radiographic response criteria.
    Swiecicki PL; Bellile EL; Brummel CV; Brenner JC; Worden FP
    Cancer; 2021 Jan; 127(2):219-228. PubMed ID: 33079405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
    Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
    Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial.
    Guo Y; Ahn MJ; Chan A; Wang CH; Kang JH; Kim SB; Bello M; Arora RS; Zhang Q; He X; Li P; Dechaphunkul A; Kumar V; Kamble K; Li W; Kandil A; Cohen EEW; Geng Y; Zografos E; Tang PZ
    Ann Oncol; 2019 Nov; 30(11):1831-1839. PubMed ID: 31501887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma.
    Mayer EL; DeMichele A; Rugo HS; Miller K; Waks AG; Come SE; Mulvey T; Jeselsohn R; Overmoyer B; Guo H; Barry WT; Huang Bartlett C; Koehler M; Winer EP; Burstein HJ
    Ann Oncol; 2019 Sep; 30(9):1514-1520. PubMed ID: 31250880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients.
    Sato H; Tsukahara K; Okamoto I; Katsube Y; Shimizu A; Kondo T; Hanyu K; Fushimi C; Okada T; Miura K
    Acta Otolaryngol; 2019 Feb; 139(2):201-205. PubMed ID: 30794080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
    Tahara M; Kiyota N; Yokota T; Hasegawa Y; Muro K; Takahashi S; Onoe T; Homma A; Taguchi J; Suzuki M; Minato K; Yane K; Ueda S; Hara H; Saijo K; Yamanaka T
    Ann Oncol; 2018 Apr; 29(4):1004-1009. PubMed ID: 29408977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Dunn LA; Fury MG; Xiao H; Baxi SS; Sherman EJ; Korte S; Pfister C; Haque S; Katabi N; Ho AL; Pfister DG
    Ann Oncol; 2017 Oct; 28(10):2533-2538. PubMed ID: 28961834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.
    Saba NF; Hurwitz SJ; Magliocca K; Kim S; Owonikoko TK; Harvey D; Ramalingam SS; Chen Z; Rogerio J; Mendel J; Kono SA; Lewis C; Chen AY; Higgins K; El-Deiry M; Wadsworth T; Beitler JJ; Shin DM; Sun SY; Khuri FR
    Cancer; 2014 Dec; 120(24):3940-51. PubMed ID: 25103371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer.
    Desilets A; Pfister DG; Stein S; Wong W; Sherman EJ; Fetten J; Hung TKW; Kriplani A; Dunn LA; Ho AL; Michel LS
    Oral Oncol; 2024 Jul; 154():106861. PubMed ID: 38795600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
    Michel L; Ley J; Wildes TM; Schaffer A; Robinson A; Chun SE; Lee W; Lewis J; Trinkaus K; Adkins D
    Oral Oncol; 2016 Jul; 58():41-8. PubMed ID: 27311401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck.
    Trieu V; Pinto H; Riess JW; Lira R; Luciano R; Coty J; Boothroyd D; Colevas AD
    Oncologist; 2018 Jul; 23(7):764-e86. PubMed ID: 29540603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of a low dose weekly paclitaxel, carboplatin and cetuximab (PCC) regimen for metastatic or unresectable head and neck squamous cell carcinomas.
    Locke M; Kohn N; Seetharamu N
    Clin Otolaryngol; 2023 Nov; 48(6):915-919. PubMed ID: 37517814
    [No Abstract]   [Full Text] [Related]  

  • 15. Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.).
    Galetta D; Giotta F; Rosati G; Gebbia V; Manzione L; Di Bisceglie M; Borsellino N; Colucci G
    Anticancer Res; 2005; 25(6C):4445-9. PubMed ID: 16334124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
    Pontes F; Garcia AR; Domingues I; João Sousa M; Felix R; Amorim C; Salgueiro F; Mariano M; Teixeira M
    Cancer Treat Res Commun; 2021; 27():100375. PubMed ID: 33882378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
    Jimeno A; Machiels JP; Wirth L; Specenier P; Seiwert TY; Mardjuadi F; Wang X; Kapp AV; Royer-Joo S; Penuel E; McCall B; Pirzkall A; Clement PM
    Cancer; 2016 Dec; 122(24):3803-3811. PubMed ID: 27525588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck.
    Weiss J; Gilbert J; Deal AM; Weissler M; Hilliard C; Chera B; Murphy B; Hackman T; Liao JJ; Grilley Olson J; Hayes DN
    Oral Oncol; 2018 Sep; 84():46-51. PubMed ID: 30115475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study.
    Forster MD; Dillon MT; Kocsis J; Remenár É; Pajkos G; Rolland F; Greenberg J; Harrington KJ
    Eur J Cancer; 2019 Dec; 123():36-47. PubMed ID: 31648099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study.
    Grünwald V; Chirovsky D; Cheung WY; Bertolini F; Ahn MJ; Yang MH; Castro G; Berrocal A; Sjoquist K; Kuyas H; Auclair V; Guillaume X; Joo S; Shah R; Harrington K;
    Oral Oncol; 2020 Mar; 102():104526. PubMed ID: 31978755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.